Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00407784|
Recruitment Status : Unknown
Verified March 2007 by Erasmus Medical Center.
Recruitment status was: Recruiting
First Posted : December 5, 2006
Last Update Posted : March 7, 2007
|Condition or disease||Intervention/treatment|
|Hyperaldosteronism Hypertension||Drug: eplerenone|
Although primary aldosteronism (PA) was formerly seen as a rare cause of hypertension, this condition is now thought to be the commonest cause of secondary hypertension, with the prevalence ranging up to 10-15 % of all hypertensives. Identification of patients with PA allows for specific treatment, for instance unilateral adrenalectomy in case of an aldosterone-producing adenoma or the administration of an aldosterone-receptor antagonist in case of bilateral adrenal hyperplasia.
Since the introduction of the aldosterone-renin ratio (ARR) as a screening tool for PA in 1981, there has been considerable debate about the diagnostic value. The values for aldosterone and renin are highly dependent on many factors, including posture, time of day and medication. Also, the cut-off values for the identification of PA remain controversial.
This study aims to evaluate the test characteristics of the ARR in a population of patients with therapy-resistant hypertension, the dependence of the ARR on medication type and the predictive value on the response on eplerenone, a selective aldosterone-receptor antagonist.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Observational Model:||Defined Population|
|Official Title:||Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study.|
|Study Start Date :||January 2007|
|Estimated Study Completion Date :||November 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407784
|Contact: Pieter Jansen, MD||+31(0)-email@example.com|
|Contact: A.H. van den Meiracker, MD, PhD||+31(0)-firstname.lastname@example.org|
|Academical Medical Center||Not yet recruiting|
|VU medical Center||Not yet recruiting|
|IJsselland Hospital||Not yet recruiting|
|Capelle aan de IJssel, Netherlands|
|Beatrix Hospital||Not yet recruiting|
|University Medical Center St. Radboud||Not yet recruiting|
|Erasmus Medical Center||Recruiting|
|MCRZ, lokation Zuider/Clara||Not yet recruiting|
|Oogziekenhuis||Not yet recruiting|
|Sint Franciscus Gasthuis||Not yet recruiting|
|Vlietland Hospital||Not yet recruiting|
|Ruwaard van Putten Hospital||Not yet recruiting|
|Twee Steden Ziekenhuis||Not yet recruiting|
|Principal Investigator:||A.H. van den Meiracker, MD, PhD||Erasmus Medical Center|